x hide permanently

DaVita officials expound on potential acquistions with cash windfall

Denver Business Journal

Flush with $4.9 billion in cash from the pending sale of its medical group and as much as $130 million in expected benefits from federal tax reform, DaVita Inc. (NYSE: DVA) CEO Kent Thiry said Tuesday that the company will look to repurchase shares, grow its kidney-care business and make “a limited number of investments” in other health-care companies.